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Abstract: Bacterial pathogens that are multi-drug resistant compromise the effectiveness 
of treatment when they are the causative agents of infectious disease. These multi-drug 
resistance  mechanisms  allow  bacteria  to  survive  in  the  presence  of  clinically  useful 
antimicrobial  agents,  thus  reducing  the  efficacy  of  chemotherapy  towards  infectious 
disease. Importantly, active multi-drug efflux is a major mechanism for bacterial pathogen 
drug resistance. Therefore, because of their overwhelming presence in bacterial pathogens, 
these active multi-drug efflux mechanisms remain a major area of intense study, so that 
ultimately measures may be discovered to inhibit these active multi-drug efflux pumps. 
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1. Introduction: Antimicrobial Resistance and Drug Efflux Pumps 
Morbidity and mortality rates caused by infectious microbial agents represent serious public health 
concerns. Pathogenic bacteria are causative agents of infectious disease in all body systems and are 
particularly serious due to  their consequences  economically, socially, and in  regards to  quality of  
life [1–3]. Thus, it is critical that a clear understanding of the biological aspects of infectious disease 
be made known so that eventually infectious disease morbidity and mortality are curtailed, if not 
eventually  eradicated.  Pathogenic  bacteria  have  devised  virulence  factors,  such  as  drug  resistance 
determinants, that facilitate pathogenesis in human patients. Unfortunately, many of these bacterial 
virulence factors are poorly understood at the molecular level. Thus, it is critical that such virulence 
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factors  be  understood  mechanistically  so  that  they  may  be  used  as  targets  for  chemotherapy. 
Antimicrobial  agents  are  indicated  for  bacterial  infectious  disease  treatment  and  represent  a  good 
means of combating infectious disease [4]. Regrettably, many pathogenic bacteria have acquired or 
developed  resistance  mechanisms,  which  work  against  anti-bacterial  drugs  [5,6].  Further,  use  and 
abuse  of  individual  antimicrobial  agents  in  clinical  settings  have  selected  for  variant  bacterial 
pathogens  that  are  naturally  resistant  to  anti-bacterial  drugs  [7].  In  fact,  selection  of  single-drug 
resistance  often  has  led  to  selection  of  multi-drug  resistance  in  pathogenic  bacteria  [8].  Such  
multi-drug  resistant  bacterial  pathogens  compromise  chemotherapeutic  efforts  and  enhance  both 
morbidity and mortality rates in humans [5,6]. Therefore, multi-drug resistant mechanisms represent 
extremely  good  targets  for  studies  towards  the  efforts  in  the  effective  treatment  of  infectious  
disease [9,10]. Among various reasons for the development of antibiotic resistance in bacteria, overuse 
is considered the most important, though this does not explain the presence of antibiotic resistance in 
non-pathogenic environmental bacteria which are not exposed to antibiotics [11]. Many species of 
bacteria are now known to have armed themselves with the means of fighting toxic compounds in 
nature, and such abilities have manifested as antibiotic resistance mechanisms in human pathogenic 
bacteria.  While  the  evolution  of  antibiotic  resistance  in  response  to  the  toxic  compounds  is 
straightforward and easy to comprehend, bacteria on the other hand, possess complex machineries, 
which extrude antibiotics as their secondary function. These membrane bound multidrug resistance 
(MDR)  efflux  pumps  are  found  in  all  bacteria  and  their  primary  functions  could  be  other  than 
antibiotic  resistance,  which  include  maintenance  of  intracellular  solute  concentrations  or  the  cell 
homeostasis,  extrusion  of  toxic  byproducts  of  metabolism  or  transport  of  amino  acids  and  
nucleotides [12–15]. Efflux pump-mediated resistance to single or multiple antimicrobial agents has 
not  only  raised  serious  concerns  but  also  has  constricted  the  treatment  options  against  bacterial 
infections [13]. Efflux pumps reduce the accumulation of antibiotics inside of the bacterial cells, and 
the slow phase in which the process of antibiotic efflux takes place provides sufficient time for the 
bacterium to adapt to the antibiotics and become resistant through mutations or alteration of antibiotic 
targets [16]. Further, the over-expression of efflux pumps enhances the resistances to antimicrobials [17]. 
Based on the sequence comparison, efflux pumps are grouped into five major categories: The major 
facilitator superfamily (MFS), the adenosine triphosphate (ATP)-binding cassette (ABC) family, the 
resistance-nodulation-division (RND) family, the small multidrug resistance (SMR) family and the 
multidrug and toxic compound extrusion family [18–27]. Efflux pumps are now known to confer 
resistance to almost all classes of antibiotics [19]. 
This review is focused mainly on efflux pumps of the MFS from Gram-negative and Gram-positive 
bacteria, current trends, and the future prospects for understanding the structure-functions relationships 
in drug efflux proteins. 
2. Efflux of Tetracycline by TetA, A Key Drug Efflux Pump 
Active efflux of antimicrobial agents was first discovered by Levy in which active extrusion was 
demonstrated of the tetracyclines from bacterial host cells harboring plasmid pBR322 [28,29]. Bacteria 
are able to resist the tetracyclines by way of active efflux via the TetA family of efflux pumps [30]. 
The TetA family of efflux pumps are grouped into two major groups: The first group is comprised of Int. J. Mol. Sci. 2012, 13  4486 
 
chromosomally-encoded 12-TMS efflux pumps, such as Tet(A), Tet(B), Tet(C) and Tet(D) [30–34], 
found  in  Gram-negative  bacteria,  while  the  second  group  comprises  plasmid-encoded  Tet(K) 
Staphylococcus aureus and Tet(L) found in Bacillus spp., Staphylococcus, and Streptococcus spp. [35]. 
Tet(K) and Tet(L) are 14-TMS efflux pumps [36,37]. Early work by Griffith and Henderson discovered 
shared  homology  between  mammalian  and  bacterial  sugar  transporters  [38,39],  establishing  the 
presence of the very large major facilitator superfamily of related symporters and antiporters with 
single- and multiple-drug substrates [24,40]. It was of tremendous interest that single- and multi-drug 
efflux pumps were homologous [24,41–44]. Implicit in this work was the presence of highly conserved 
amino  acid  sequence  motifs  shared  in  members  of  the  MFS [24,27].  Later,  a  mutational  analysis 
showed that a highly conserved glycine residue in the so-called antiporter motif (Motif C) of the 
TetA(C) efflux pump was necessary for conferring resistance to tetracycline [32]. This glycine was 
found in  Motif C,  a highly conserved motif in  TMS5 in  antiporters of the MFS [40]. Additional 
elements of Motif C were shown to be required for single and multidrug transport in the efflux pumps 
CaMdr1p, QacA, Mdt(A) from Lactococcus garvieae and Lactococcus lactis, Tet(B), Tet(K), Tet(L), 
and VAChT [32,45–54]. Inhibitors of tetracycline efflux were discovered [55–57]. Analyses of the 
structure-function relationships of single- and multi-drug efflux pumps may indentify key residues for 
discovery of efflux inhibitors. Therefore, identification of functionally conserved regions within efflux 
pumps should be useful for design of efflux pump inhibitors [58,59]. 
3. MdfA from Escherichia coli 
MdfA, found in Escherichia coli, is a secondary multidrug efflux pump made up of 410 amino 
acids  encoded  by  a  chromosomal  gene  cmr  [60].  Based  on  phoA  (alkaline  phosphatase)  and  cat 
(chloramphenicol acetyl transferase) gene fusion studies, MdfA has 12 transmembrane helices [61]. 
Though a crystal structure is not currently available, predicted 3D structure has been able to reveal 
some interesting features of MdfA such as the presence of a large cavity with a putative substrate 
binding function with three amino acids Glu26, Asp34 and Asp132 with critical roles in the interaction 
of MdfA with the drugs [62]. Of these, Glu26 has been shown to be important for the transport of 
cationic substrates [60]. Mutations changing Glu26 into Ala, Asn, His, Leu, and Asp severely affects 
the  efflux  of  neutral  substrates,  while  the  amino  acids  Gln26  and  Ile26  confer  higher  levels  of 
resistance by MdfA to the same substrates [61]. On the other hand, a Glu26Thr mutation completely 
abolishes cationic drug transport by MdfA, and this effect is greatly reverted by a second site mutation 
Val335Glu/Asp  [61].  In  addition  to  multidrug  resistance,  MdfA  performs  a  further  function  of 
maintaining the physiological pH of the cell [62]. 
4. EmrD-3 from Vibrio cholerae 
Many of the antibiotic efflux pumps identified in the pathogenic V. cholerae belong to the MATE 
and RND family of efflux proteins [63–65]. EmrD-3, identified in an O1 strain of V. cholerae, is an 
efflux  pump  of  MFS  family  with  12  transmembrane  segments  (TMS)  [66].  Membrane  proteins 
homologues  of  EmrD-3  are  widely  distributed  among  the  Gram-positive  and  -negative  bacteria, 
including several Vibrio and Bacillus spp. EmrD-3 is closely related to the Bcr/CflA subfamily of 
membrane  proteins,  which  includes  Bcr  (bicyclomycin  resistance  protein)  in  E.  coli,  FloR Int. J. Mol. Sci. 2012, 13  4487 
 
(chloramphenicol and florfenicol resistance), in Salmonella enterica serotype Typhimurium DT104 
and CmlA (chloramphenicol resistance) in Pseudomonas. The H
+-antiport activity of EmrD-3 has been 
demonstrated  by  ethidium  bromide  efflux  and  accumulation  assays  [66].  Among  the  various 
antimicrobials actively extruded by EmrD-3 are linezolid, rifampin, trimethorprim, erythromycin, and 
chloramphenicol. Of these, the highest resistance was conferred to the oxzolidinone drug linezolid and 
it is speculated that linezolid may be the preferred efflux substrate by EmrD-3. The ability of EmrD-3 
to actively extrude linezolid and the presence of its homologues in Gram-positive bacteria raises new 
concerns  since  the  oxazolidinone  class  of  drugs,  to  which  linezolid  belongs,  are  used  to  treat  
Gram-positive bacterial infections by Streptococcus spp., vancomycin-resistant Enterococcus faecium, 
and methicillin-resistant Staphylococcus aureus (MRSA) [67]. Resistance to linezolid is attributed to a 
point mutation in the peptidyl transferase of 23S rRNA and the involvement of efflux pumps is not 
well  known  [68].  Efflux  pumps,  being  integral  membrane  proteins,  were  thought  to  extrude  only 
hydrophobic compounds. However, efflux of linezolid, which is a hydrophilic drug, by EmrD-3 and 
other efflux pumps such as AcrAB, has changed this hypothesis [66,69]. The discovery of the role of 
EmrD-3 in linezolid resistance will lead to the identification of similar efflux pumps in Gram-positive 
bacteria. Currently no crystal or predicted 3D structures are available for EmrD-3. 
5. LmrS from Staphylococcus aureus 
LmrS  is  an  efflux  pump  of  the  MFS  family  with  14  TMS  identified  in  a  clinically-isolated 
methicillin-resistant Staphylococcus aureus strain [70]. Unlike the QacA-family of plasmid-encoded 
efflux pumps, LmrS is encoded by a chromosomal gene. Proteins homologous to LmrS are widely 
distributed among the Gram-positive group of bacteria that includes Staphylococcus, Enterococcus, 
Bacillus,  Lactobacillus  and  Listeria.  The cloned lmrS  gene conferred  high  antibiotic resistance to 
lincomycin,  kanamycin,  fusidic  acid,  linezolid,  trimethoprim,  florfenicol,  chloramphenicol, 
erythromycin,  streptomycin,  fusidic  acid,  and  kanamycin.  The  lincomycin  resistance  conferred  by 
LmrS is further supported by an amino acid sequence similarity of 62% with the lincomycin resistance 
protein LmrB of Bacillus subtilis. Significantly, LmrS confers clinical levels of resistance to linezolid 
and fusidic acid, two important antimicrobials with strong activity against MRSA. Interestingly, the 
lmrS gene is present in both methicillin-resistant and -sensitive S. aureus strains. Thus, it needs to be 
determined  if  other  regulatory  factors  play  any  role  in  the  expression  of  lmrS  in  S.  aureus.  
A preliminary study has shown constitutive expression of lmrS in clinical strains of S. aureus [70]. 
6. Mdt(A) from Lactococcus lactis and L. garvieae 
The  multiple  drug  transporter  Mdt(A)  is  a  plasmid-encoded  efflux  pump  found  in  
Lactococcus lactis [51]. The protein has 418 amino acids that fold into 12 TMS, and is a member of 
the MFS with some interesting structural differences [51]. Mdt(A) has two antiporter motifs (motif C) 
on TMS5 and TMS9, and also a putative ATP-binding site. The substrates for Mdt(A) include 14-,  
15-  and  16-membered  macrolides,  lincosamides,  streptogramins  and  tetracyclines  [51].  Recently,  
a multidrug-efflux pump EfmA of Enterococcus faecium has been reported to have very high sequence 
similarity (86%) with Mdt(A) [71]. However, it is not known if Mdt(A) is H
+ dependent, though the 
addition of glucose resulted in efflux. However, protonophores such as CCCP did not inhibit the efflux Int. J. Mol. Sci. 2012, 13  4488 
 
activity [51]. The molecular mechanism and the structure-function relationship responsible for drug 
transport by Mdt(A) remains to be elucidated. A recent study describes the presence of a mutated Mdt(A) 
in Lactococcus garvieae that did not confer elevated resistance to erythromycin or tetracycline [48]. The 
mutations were Val154Phe and Ile296Val in TMS5 and TMS9 respectively, the two antiporter motifs 
(motif C) of Mdt(A) [48]. Unlike in L. lactis, Mdt(A) of L. garvieae is chromosomally encoded [48]. 
7. QacA and QacB from Staphylococcus aureus 
QacA is encoded by plasmid-borne genes in multidrug resistant Staphylococcus aureus [72–74]. 
Subsequently,  the  qacA  gene  was  found  to  be  widespread  among  Staphylococcus  aureus  strains 
isolated  from  clinical  environments  [75].  The  QacA  efflux  pump  extrudes  structurally  diverse 
monovalent and divalent cationic substrates, the most prominent among them being the quaternary 
ammonium compounds or the Qacs [76,77]. QacA is 514 amino acids long, traverses the membrane  
14 times and is energized by protons (H
+) [78]. QacA was the first efflux protein of the MFS family 
with 14 TMS. QacB, which is also plasmid-encoded, confers resistance only to monovalent cationic 
substrates, confers little or no resistance to divalent cationic substrates, and the nucleotide sequence 
that encodes QacB differs from QacA only by seven nucleotides [79]. Structure-function analyses have 
demonstrated the functional importance of key amino acid residues in the transport of drug substrates 
by QacA, making these critical residues prime targets for drug design studies of putative efflux pump 
inhibitors [49,80–85]. The presence of acidic residues at amino acid positions 322 or 323 is essential 
for QacA or QacB to efflux divalent cations [79]. The expression of qacA genes is regulated by a 
transcription regulator, QacR, which belongs to the tetR family of regulators [86]. 
8. NorA, NorB and NorC from Staphylococcus aureus 
NorA, the first chromosomally-encoded efflux pump identified in Staphylococcus aureus is made 
up of 388 amino acids, with 12 TMS [87,88]. The norA gene is present in all of the whole genome 
sequences of Staphylococcus aureus strains currently available in the GenBank. Initially, norA was 
thought to specifically efflux the quinolone drug norfloxacin, but subsequently was found to confer 
resistance to a number of antimicrobials, including chloramphenicol [75,85]. The expression of norA is 
regulated by mgrA, a member of a marR group of transcriptional regulators [89]. NorB and NorC are 
each made up of 462 amino acids, both efflux pumps are organized into 14 TMS and confer resistance 
to quinolones, such as ciprofloxacin, norfloxacin, and sparfloxacin [90,91]. 
9. Conclusions and Future Directions 
Bacterial  multi-drug  efflux  pumps  constitute  a  major  mechanism  for  conferring  multi-drug 
resistance in pathogenic bacteria that cause infectious disease [76,92]. Multi-drug efflux pumps reside 
in the biological membrane and actively extrude antimicrobial agents from pathogenic bacterial cells [92], 
thus  conferring  multi-drug  resistance.  Thus,  multi-drug  efflux  pumps  reduce  the  efficacy  of 
chemotherapy for infection caused by bacteria that harbor these pumps, resulting in a serious health 
concern [93,94]. In order for translational science efforts to come to fruition, it will become necessary 
to identify key targets within efflux pumps to make effective inhibitors, which can then be used in Int. J. Mol. Sci. 2012, 13  4489 
 
modulation chemotherapy [9,10]. Unfortunately, it is poorly understood how these multi-drug efflux 
pumps  function  in  terms  of  the  structure-function  relationships.  Thus,  lack  of  a  clear  molecular 
analysis of the multi-drug efflux pumps prevents investigators from ultimately seeking potential efflux 
inhibitors, because they lack precise information regarding key molecular targets, such as amino acids 
that bestow drug transport. Study of the molecular biology of multi-drug efflux pumps would identify 
important amino acids that confer their active efflux function. Knowing these amino acid targets that 
confer  activity  from  a  molecular  standpoint  would  identify  critical  amino  acids  that  would serve, 
therefore, as important targets for potential inhibition of multi-drug efflux [9,10]. Thus, inhibition of 
the  multi-drug  efflux  pumps  would  aid  in  potentially  restoring  the  effectiveness  of  antimicrobial 
chemotherapy of infectious disease caused by bacteria that have multi-drug efflux pumps. Therefore, 
morbidity and mortality frequencies may be diminished, because of multi-drug efflux inhibition [9,10]. 
Study of the structure-function relationships of multi-drug efflux pumps is therefore needed, in order 
to determine the functional roles of key amino acids that convey drug efflux from pathogenic bacteria 
and make translational medicine possible. 
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